Praxis Precision Medicines raises ~$567M in underwritten public offering of common stock and pre-funded warrants

Praxis Precision Medicines, Inc.

Offering of 3,025,480 shares at $157.00 and 318,470 pre-funded warrants at $156.9999 per underlying share.
Underwriters fully exercised option for 501,592 additional shares; total net proceeds expected ~$567M.
Net proceeds to fund R&D, commercialization prep, and working capital; expected to fund operations into 2028.
Pre-funded warrants exercisable immediately with 4.99% beneficial ownership limitation (adjustable up to 19.99%).
Closing expected October 20, 2025; shares listed on Nasdaq (PRAX); pre-funded warrants not listed.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.